Verona has named Richard Bungay as the company’s chief financial officer to replace Danny Lowe.
Bungay joins the UK-based biotech initially on a part-time basis as it looks to develop its portfolio of investigational medicines for respiratory diseases.
His most recent position was as part-time CEO of fellow UK biotech Chroma Therapeutics, which focuses on the development of novel small molecules for inflammation and oncology, having previously served as the company’s chief financial officer.
Prior to his time at Chroma, Bungay was director of corporate communications and strategic planning at Celltech and spent several years as finance director within the respiratory and inflammation therapy area at AstraZeneca.
Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “Richard’s experience in financial management of innovative R&D-based businesses as well as his experience in investor relations will be invaluable to Verona Pharma as we move our key clinical programmes forward and grow the company.”